Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

31
Rounds Report: Nephros Posts Strong Preliminary Financial Results For Q2

2018-07-13 seekingalpha
The overall bioscience market traded with a mixed sentiment for the day. Nevertheless, many equities under over coverage continued to rally.
NTLA SLDB SGMO CRSP ABEO XBI ONCE RGNX NEPH EDIT ADVM IBB ABEOW

27
SGMO / Sangamo BioSciences, Inc. 8-K DIRECTOR APPOINTMENT (Current Report)

2018-06-28 sec.gov
sgmo-8k_20180628.htm UNITED STATES
SGMO

19
SGMO / Sangamo BioSciences, Inc. null

2018-06-25 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
SGMO

33
73
Sangamo Therapeutics: Investability Outlook

2018-06-13 seekingalpha
Like BioTime (BTX), which we discussed recently, Sangamo (SGMO) is another company that began the wrong way, with a platform, and then, and only recently, moved on to therapeutics. But, oh boy, what a move it has been! The company changed its name from Sangamo Biosciences to Sangamo Therapeutics to emphasize that change in direction after its new CEO Sandy Macrae took over, and within about 24 months, changed from a sleepy lab-oriented laggard to a company with multiple deals and pipeline assets.
CLXT SHPG SGMO BTX SIAL PFE BIVV

31
SGMO / Sangamo BioSciences, Inc. S-8

2018-06-11 sec.gov
S-8 As filed with the Securities and Exchange Commission on June 11, 2018 Registration No. 333-
SGMO

49
Sangamo Banks On Gene Editing Technology To Scale New Highs

2018-06-07 seekingalpha
Sangamo Therapeutics Inc. (NASDAQ:SGMO) has established itself as a leader in the gene editing field. It is the leader in ZFN (Zinc Finger nuclease) technology used for gene editing and has strong IP in the field. The company has been developing and outlicensing this technology for many years. SGMO stock has kept pace with the developments shown by the company. The stock is currently trading considerably lower from its previous highs and presents a good purchase point.
SGMO NVS GBT SNY

37
After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall

2018-06-05 investorplace
Quite often in stock markets, companies that offer something novel and unique attract speculators. So, when Crispr Therapeutics AG (NASDAQ:CRSP) quadrupled from 52-week lows, investors naturally questioned its valuation against its prospects.
VRTX GILD SGMO CRSP

19
WDDD / Worlds, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-21 fintel.io
Worlds, Inc. (OTC:WDDD) has 2 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,820,000 shares. Largest shareholders include Worlds Inc, and Hudson Valley Investment Advisors Inc /adv. Worlds, Inc. (OTC:WDDD) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
WDDD SGMO

25
WHLRD / Wheeler Real Estate Investment Trust, Inc., 8.75% Series D Cumulative Convertible Preferred Stock - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-21 fintel.io
Wheeler Real Estate Investment Trust, Inc., 8.75% Series D Cumulative Convertible Preferred Stock (NASDAQ:WHLRD) has 19 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,899,539 shares. Largest shareholders include Orinda Asset Management LLC, FMR LLC / Fidelity, Resource America, Inc., JCP Investment Management, LLC, Snow Park Capital Partners, Lp, Forward Management, LLC, LDR Capital Management LLC, RMR Advisors LLC, Wolverine Asset Management Llc, and Knott David M.
WHLRD WHLRW SGMO REXI WHLR WHIR WHLRP

20
SODI / Solitron Devices, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-21 fintel.io
Solitron Devices, Inc. (OTC:SODI) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 157,807 shares. Largest shareholders include Olesen Value Fund L.P.. Solitron Devices, Inc. (OTC:SODI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
SODI SGMO

19
BKUH / Bakhu Holdings, Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-21 fintel.io
Bakhu Holdings, Corp. (OTC:BKUH) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 335,000 shares. Largest shareholders include Oz Corp. Bakhu Holdings, Corp. (OTC:BKUH) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
SGMO BKUHD BKUH

19
NESR / National Energy Services Reunited Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-21 fintel.io
National Energy Services Reunited Corp. (NASDAQ:NESR) has 39 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 24,239,502 shares. Largest shareholders include MMCAP International Inc. SPC, Nesr Holdings Ltd., K2 Principal Fund, L.p., Oxford Asset Management, Picton Mahoney Asset Management, EdgePoint Investment Group Inc.
NESR SGMO NESRU

69
Rounds Report: Omeros Rallied Robustly While Stellar FDA Due Diligence To Help Orphan Disease Innovators

2018-05-16 seekingalpha
The strong momentum of the previous week continues, as the bioscience market traded significantly higher today. Many firms under our coverage enjoyed substantial profits.
OMER NKTR ATRA SGMO CRSP IBB XBI

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

1h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Silicon Investor Message Boards

This table lists all message boards related to SGMO / Sangamo BioSciences, Inc. on message board site Silicon Investor.

Sangamo BioSciences, Inc. SGMO u0027functional cureu0027 of HIV: same tech could cure more diseases
CUSIP: 800677106